|
시장보고서
상품코드
2020334
니코틴 껌 시장 규모, 점유율, 성장 및 세계 업계 분석 : 유형 및 용도별, 지역별 인사이트 및 예측(2026-2034년)Nicotine Gum Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034 |
||||||
니코틴 껌 시장의 성장 요인
세계 니코틴 껌 시장은 2025년에 17억 9,000만 달러로 평가되었습니다. 2026년에는 18억 8,000만 달러, 2034년에는 28억 5,000만 달러에 달할 것으로 예상되며, 2026-2034년 5.36%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다. 흡연의 유해성에 대한 인식이 높아지고 니코틴 대체요법(NRT)의 보급이 확대됨에 따라 이 시장은 꾸준히 성장하고 있습니다.
니코틴 껌은 금단증상을 완화하여 금연을 돕기 위해 고안된 FDA 승인 금연 보조제입니다. 구강 점막을 통해 일정량의 니코틴을 방출하여 흡연 욕구를 억제하고 단계적 금연을 지원합니다.
시장 주요 동향
2025년 북미는 건강 지향적인 소비자들이 많고, 주요 브랜드의 존재감이 강해 40.94%의 점유율로 시장을 주도했습니다. 미국 시장은 제품 혁신과 정부 주도의 금연 정책에 힘입어 2032년까지 7억 2,692만 달러에 달할 것으로 예상되며, 큰 폭의 성장이 예상됩니다.
2mg 니코틴 껌 부문은 경증 흡연자에게 적합하고 다양한 향이 널리 보급되어 있기 때문에 가장 큰 점유율을 유지할 것으로 예측됩니다.
시장 동향
시장에서 눈에 띄는 트렌드로는 건강한 라이프 스타일로의 전환과 금연에 대한 관심 증가를 들 수 있습니다. 세계 각국 정부는 광고 규제, 공공장소에서의 흡연 제한, 담배 제품에 대한 세금 인상 등 엄격한 규제를 시행하고 있습니다.
이러한 조치와 더불어, 흡연자들이 니코틴 껌과 같은 더 안전한 대체품을 채택하도록 장려하기 위한 홍보 캠페인이 강화되고 있습니다. 또한, 각 제조업체들은 소비자의 수용성과 만족도를 높이기 위해 혁신적인 맛과 개선된 제형을 도입하고 있습니다.
시장 성장 촉진요인
확대되는 금연 캠페인
정부 및 비정부기구는 금연 프로그램을 적극적으로 추진하고 있습니다. 이러한 노력으로 껌, 로젠지, 패치 등 니코틴 대체요법에 대한 인식이 크게 향상되고 있습니다.
상담 프로그램과 NRT 제품의 시너지 효과로 금연 성공률이 최대 50-60%까지 향상되는 것으로 나타났으며, 이는 시장 성장을 견인하고 있습니다.
흡연 관련 질환 증가
폐암, 심혈관 질환, 호흡기 질환 등의 발병률 증가는 사람들에게 금연을 촉구하고 있습니다. 이로 인해 특히 의료 기관과 재활센터에서 니코틴 껌에 대한 수요가 증가하고 있습니다.
시장 성장 억제요인
성장세를 보이고 있는 반면, 니코틴 껌에 따른 부작용으로 인해 시장은 문제에 직면해 있습니다. 메스꺼움, 현기증, 심박수 증가, 소화불량 등 일반적인 부작용은 장기적인 사용을 방해할 수 있습니다.
또한, 부적절한 사용이나 과다 복용은 위장 장애를 유발할 수 있으며, 일부 소비자의 채택을 제한하는 요인이 될 수 있습니다.
세분화 분석
유형별
- 2mg 니코틴 껌: 경증 흡연자에게 적합하고 쉽게 구할 수 있어 2026년 59.08%의 점유율을 차지하며 시장을 장악했습니다.
- 기타 강도(예: 4mg) : 헤비 스모커에게 이용되고 있으며, 꾸준한 성장이 예상됩니다.
유통채널별
- 약국: 소비자 신뢰도가 높고, 판매가 규제되어 있어 2026년 50.99%로 가장 큰 점유율을 차지했습니다.
- 온라인 스토어: 편의성, 할인, 택배 옵션으로 인해 가장 빠른 성장이 예상됩니다.
지역별 분석
- 북미: 2025년 7억 3,000만 달러로 가장 큰 시장이 될 것이며, 높은 인지도와 제품 혁신에 힘입어 2026년에는 7억 6,000만 달러에 달할 것으로 예측됩니다.
- 유럽: 2025년 5억 3,000만 달러를 차지할 것으로 예상되며, 엄격한 흡연 규제와 금연 프로그램이 뒷받침하고 있습니다.
- 아시아태평양: 가장 빠르게 성장하고 있는 지역으로, 인도, 일본 등의 국가에서 수요 증가와 규제적 지원을 배경으로 2025년에는 3억 3,000만 달러, 2026년에는 3억 5,000만 달러에 달할 것으로 예상되고 있습니다.
- 라틴아메리카, 중동 및 아프리카: 의료에 대한 인식이 높아지고 의료 접근성이 개선되면서 완만한 성장이 예상됩니다.
목차
제1장 서론
제2장 주요 요약
제3장 시장 역학
제4장 주요 인사이트
LSH 26.05.14Growth Factors of nicotine gum Market
The global nicotine gum market was valued at USD 1.79 billion in 2025 and is projected to grow to USD 1.88 billion in 2026, reaching USD 2.85 billion by 2034, registering a CAGR of 5.36% during 2026-2034. The market is witnessing steady growth due to increasing awareness regarding the harmful effects of smoking and rising adoption of nicotine replacement therapies (NRTs).
Nicotine gum is an FDA-approved smoking cessation aid designed to help individuals quit tobacco use by reducing withdrawal symptoms. It delivers controlled doses of nicotine through the oral mucosa, thereby suppressing cravings and supporting gradual cessation.
Key Market Insights
North America dominated the market in 2025 with a 40.94% share, supported by a high number of health-conscious consumers and strong presence of leading brands. The U.S. market is expected to grow significantly, reaching USD 726.92 million by 2032, driven by product innovation and government-led anti-smoking initiatives.
The 2MG nicotine gum segment is expected to retain the largest share due to its suitability for light smokers and widespread availability in various flavors.
Market Trends
A prominent trend in the market is the rising shift toward healthier lifestyles and smoking cessation. Governments worldwide are implementing strict regulations, including advertising bans, public smoking restrictions, and higher taxation on tobacco products.
These measures, along with increasing public awareness campaigns, are encouraging smokers to adopt safer alternatives such as nicotine gum. Additionally, manufacturers are introducing innovative flavors and improved formulations to enhance consumer acceptance and satisfaction.
Market Drivers
Growing Anti-Smoking Campaigns
Government and non-government organizations are actively promoting smoking cessation programs. These initiatives are significantly increasing awareness about nicotine replacement therapies, including gums, lozenges, and patches.
The combined effect of counseling programs and NRT products has been shown to improve quit success rates by up to 50-60%, thereby driving market growth.
Rising Prevalence of Smoking-Related Diseases
The increasing incidence of diseases such as lung cancer, cardiovascular disorders, and respiratory illnesses is encouraging individuals to quit smoking. This has led to higher demand for nicotine gum, particularly in healthcare institutions and rehabilitation centers.
Market Restraints
Despite positive growth trends, the market faces challenges due to side effects associated with nicotine gum. Common issues such as nausea, dizziness, increased heart rate, and indigestion may discourage prolonged use.
Additionally, improper usage or excessive consumption can lead to gastrointestinal discomfort, which may limit adoption among certain consumers.
Segmentation Analysis
By Type
- 2MG Nicotine Gum: Dominated the market with a 59.08% share in 2026, owing to its suitability for light smokers and easy availability.
- Other Strengths (e.g., 4MG): Used by heavy smokers and expected to grow steadily.
By Distribution Channel
- Pharmacies: Held the largest share of 50.99% in 2026, due to high consumer trust and regulated sales.
- Online Stores: Expected to witness the fastest growth due to convenience, discounts, and home delivery options.
Regional Analysis
- North America: Largest market with USD 0.73 billion in 2025, projected to reach USD 0.76 billion in 2026, driven by strong awareness and product innovation.
- Europe: Accounted for USD 0.53 billion in 2025, supported by strict smoking regulations and cessation programs.
- Asia Pacific: Fastest-growing region, valued at USD 0.33 billion in 2025 and USD 0.35 billion in 2026, driven by rising demand and regulatory support in countries like India and Japan.
- Latin America & Middle East & Africa: Witnessing gradual growth due to increasing awareness and improving healthcare access.
Competitive Landscape
Key players in the nicotine gum market include GlaxoSmithKline plc, Johnson & Johnson, Novartis Consumer Health, ITC Limited, Cipla Health Limited, Perrigo Company plc, and Fertin Pharma. These companies focus on product innovation, expanding distribution channels, and strategic partnerships to strengthen their market presence.
Conclusion
The global nicotine gum market is expected to grow from USD 1.79 billion in 2025 to USD 2.85 billion by 2034, driven by rising health awareness, increasing anti-smoking initiatives, and growing demand for nicotine replacement therapies. Although side effects and usage limitations pose challenges, ongoing product innovation and expanding accessibility through online and retail channels are expected to support market growth. Overall, the market presents stable growth opportunities as more consumers shift toward healthier lifestyles and smoking cessation solutions.
Segmentation By Type
- 2 mg
- 4 mg
- 6 mg
By Distribution Channel
- Supermarkets and Hypermarkets
- Pharmacies
- Online Stores
By Geography
- North America (By Type, By Distribution Channel, & By Country)
- U.S. (By Distribution Channel)
- Canada (By Distribution Channel)
- Mexico (By Distribution Channel)
- Europe (By Type, By Distribution Channel, & By Country)
- U.K. (By Distribution Channel)
- Germany (By Distribution Channel)
- France (By Distribution Channel)
- Italy (By Distribution Channel)
- Spain (By Distribution Channel)
- Russia (By Distribution Channel)
- Rest of Europe (By Distribution Channel)
- Asia Pacific (By Type, By Distribution Channel, & By Country)
- China (By Distribution Channel)
- India (By Distribution Channel)
- Australia (By Distribution Channel)
- Japan (By Distribution Channel)
- Rest of Asia- Pacific (By Distribution Channel)
- South America (By Type, By Distribution Channel, & By Country)
- Brazil (By Distribution Channel)
- Argentina (By Distribution Channel)
- Rest of South America (By Distribution Channel)
- Middle East & Africa (By Type, By Distribution Channel, & By Country)
- UAE (By Distribution Channel)
- South Africa (By Distribution Channel)
- Rest of the Middle East & Africa (By Distribution Channel)
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Emerging Trends
4. Key Insights
- 4.1. Overview of the Parent/Related Markets
- 4.2. Industry SWOT Analysis
- 4.3. Supply Chain and Regulatory Analysis
- 4.4. Recent Industry Developments - Policies, Partnerships, New Product Launches, and Mergers & Acquisitions
- 4.5. Qualitative Analysis Related to COVID-19
- 4.5.1. Impact of COVID-19 on the Market
- 4.5.2. Supply Chain Challenges amidst Pandemic
- 4.5.3. Potential Opportunities due to this Global Crisis
5. Global Nicotine Gum Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Key Findings / Summary
- 5.2. Market Size Estimates and Forecast
- 5.2.1. By Type
- 5.2.1.1. 2 MG
- 5.2.1.2. 4 MG
- 5.2.1.3. Hymenoptera
- 5.2.1.4. Orthopetra
- 5.2.1.5. 6 MG
- 5.2.2. By Distribution Channel
- 5.2.2.1. Supermarkets & Hypermarkets
- 5.2.2.2. Pharmacy
- 5.2.2.3. Online Retail
- 5.2.3. By Region
- 5.2.3.1. North America
- 5.2.3.2. Europe
- 5.2.3.3. Asia Pacific
- 5.2.3.4. South America
- 5.2.3.5. Middle East & Africa
- 5.2.1. By Type
6. North America Nicotine Gum Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Key Findings / Summary
- 6.2. Market Size Estimates and Forecast
- 6.2.1. By Type
- 6.2.1.1. 2 MG
- 6.2.1.2. 4 MG
- 6.2.1.3. 6 MG
- 6.2.2. By Distribution Channel
- 6.2.2.1. Supermarkets & Hypermarkets
- 6.2.2.2. Pharmacy
- 6.2.2.3. Online Retail
- 6.2.3. By Country (Value)
- 6.2.3.1. U.S.
- 6.2.3.1.1. By Distribution Channel
- 6.2.3.1.1.1. Supermarkets & Hypermarkets
- 6.2.3.1.1.2. Pharmacy
- 6.2.3.1.1.3. Online Retail
- 6.2.3.1.1. By Distribution Channel
- 6.2.3.2. Canada
- 6.2.3.2.1. By Distribution Channel
- 6.2.3.2.1.1. Supermarkets & Hypermarkets
- 6.2.3.2.1.2. Pharmacy
- 6.2.3.2.1.3. Online Retail
- 6.2.3.2.1. By Distribution Channel
- 6.2.3.3. Mexico
- 6.2.3.3.1. By Distribution Channel
- 6.2.3.3.1.1. Supermarkets & Hypermarkets
- 6.2.3.3.1.2. Pharmacy
- 6.2.3.3.1.3. Online Retail
- 6.2.3.3.1. By Distribution Channel
- 6.2.3.1. U.S.
- 6.2.1. By Type
7. Europe Nicotine Gum Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Key Findings / Summary
- 7.2. Market Size Estimates and Forecast
- 7.2.1. By Type
- 7.2.1.1. 2 MG
- 7.2.1.2. 4 MG
- 7.2.1.3. 6 MG
- 7.2.2. By Distribution Channel
- 7.2.2.1. Supermarkets & Hypermarkets
- 7.2.2.2. Pharmacy
- 7.2.2.3. Online Retail
- 7.2.3. By Country (Value)
- 7.2.3.1. Germany
- 7.2.3.1.1. By Distribution Channel
- 7.2.3.1.1.1. Supermarkets & Hypermarkets
- 7.2.3.1.1.2. Pharmacy
- 7.2.3.1.1.3. Online Retail
- 7.2.3.1.1. By Distribution Channel
- 7.2.3.2. France
- 7.2.3.2.1. By Distribution Channel
- 7.2.3.2.1.1. Supermarkets & Hypermarkets
- 7.2.3.2.1.2. Pharmacy
- 7.2.3.2.1.3. Online Retail
- 7.2.3.2.1. By Distribution Channel
- 7.2.3.3. Italy
- 7.2.3.3.1. By Distribution Channel
- 7.2.3.3.1.1. Supermarkets & Hypermarkets
- 7.2.3.3.1.2. Pharmacy
- 7.2.3.3.1.3. Online Retail
- 7.2.3.3.1. By Distribution Channel
- 7.2.3.4. U.K.
- 7.2.3.4.1. By Distribution Channel
- 7.2.3.4.1.1. Supermarkets & Hypermarkets
- 7.2.3.4.1.2. Pharmacy
- 7.2.3.4.1.3. Online Retail
- 7.2.3.4.1. By Distribution Channel
- 7.2.3.5. Spain
- 7.2.3.5.1. By Distribution Channel
- 7.2.3.5.1.1. Supermarkets & Hypermarkets
- 7.2.3.5.1.2. Pharmacy
- 7.2.3.5.1.3. Online Retail
- 7.2.3.5.1. By Distribution Channel
- 7.2.3.6. Rest of Europe
- 7.2.3.6.1. By Distribution Channel
- 7.2.3.6.1.1. Supermarkets & Hypermarkets
- 7.2.3.6.1.2. Pharmacy
- 7.2.3.6.1.3. Online Retail
- 7.2.3.6.1. By Distribution Channel
- 7.2.3.1. Germany
- 7.2.1. By Type
8. Asia Pacific Nicotine Gum Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Key Findings / Summary
- 8.2. Market Size Estimates and Forecast
- 8.2.1. By Type
- 8.2.1.1. 2 MG
- 8.2.1.2. 4 MG
- 8.2.1.3. 6 MG
- 8.2.2. By Distribution Channel
- 8.2.2.1. Supermarkets & Hypermarkets
- 8.2.2.2. Pharmacy
- 8.2.2.3. Online Retail
- 8.2.3. By Country (Value)
- 8.2.3.1. China
- 8.2.3.1.1. By Distribution Channel
- 8.2.3.1.1.1. Supermarkets & Hypermarkets
- 8.2.3.1.1.2. Pharmacy
- 8.2.3.1.1.3. Online Retail
- 8.2.3.1.1. By Distribution Channel
- 8.2.3.2. India
- 8.2.3.2.1. By Distribution Channel
- 8.2.3.2.1.1. Supermarkets & Hypermarkets
- 8.2.3.2.1.2. Pharmacy
- 8.2.3.2.1.3. Online Retail
- 8.2.3.2.1. By Distribution Channel
- 8.2.3.3. Japan
- 8.2.3.3.1. By Distribution Channel
- 8.2.3.3.1.1. Supermarkets & Hypermarkets
- 8.2.3.3.1.2. Pharmacy
- 8.2.3.3.1.3. Online Retail
- 8.2.3.3.1. By Distribution Channel
- 8.2.3.4. Australia
- 8.2.3.4.1. By Distribution Channel
- 8.2.3.4.1.1. Supermarkets & Hypermarkets
- 8.2.3.4.1.2. Pharmacy
- 8.2.3.4.1.3. Online Retail
- 8.2.3.4.1. By Distribution Channel
- 8.2.3.5. Rest of Asia Pacific
- 8.2.3.5.1. By Distribution Channel
- 8.2.3.5.1.1. Supermarkets & Hypermarkets
- 8.2.3.5.1.2. Pharmacy
- 8.2.3.5.1.3. Online Retail
- 8.2.3.5.1. By Distribution Channel
- 8.2.3.1. China
- 8.2.1. By Type
9. South America Nicotine Gum Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Key Findings / Summary
- 9.2. Market Size Estimates and Forecast
- 9.2.1. By Type
- 9.2.1.1. 2 MG
- 9.2.1.2. 4 MG
- 9.2.1.3. Hymenoptera
- 9.2.1.4. Orthopetra
- 9.2.1.5. 6 MG
- 9.2.2. By Distribution Channel
- 9.2.2.1. Supermarkets & Hypermarkets
- 9.2.2.2. Pharmacy
- 9.2.2.3. Online Retail
- 9.2.3. By Country (Value)
- 9.2.3.1. Brazil
- 9.2.3.1.1. By Distribution Channel
- 9.2.3.1.1.1. Supermarkets & Hypermarkets
- 9.2.3.1.1.2. Pharmacy
- 9.2.3.1.1.3. Online Retail
- 9.2.3.1.1. By Distribution Channel
- 9.2.3.2. Argentina
- 9.2.3.2.1. By Distribution Channel
- 9.2.3.2.1.1. Supermarkets & Hypermarkets
- 9.2.3.2.1.2. Pharmacy
- 9.2.3.2.1.3. Online Retail
- 9.2.3.2.1. By Distribution Channel
- 9.2.3.3. Rest of South America
- 9.2.3.3.1. By Distribution Channel
- 9.2.3.3.1.1. Supermarkets & Hypermarkets
- 9.2.3.3.1.2. Pharmacy
- 9.2.3.3.1.3. Online Retail
- 9.2.3.3.1. By Distribution Channel
- 9.2.3.1. Brazil
- 9.2.1. By Type
10. Middle East & Africa Nicotine Gum Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Key Findings / Summary
- 10.2. Market Size Estimates and Forecast
- 10.2.1. By Type
- 10.2.1.1. 2 MG
- 10.2.1.2. 4 MG
- 10.2.1.3. 6 MG
- 10.2.2. By Distribution Channel
- 10.2.2.1. Supermarkets & Hypermarkets
- 10.2.2.2. Pharmacy
- 10.2.2.3. Online Retail
- 10.2.3. By Country (Value)
- 10.2.3.1. South Africa
- 10.2.3.1.1. By Distribution Channel
- 10.2.3.1.1.1. Supermarkets & Hypermarkets
- 10.2.3.1.1.2. Pharmacy
- 10.2.3.1.1.3. Online Retail
- 10.2.3.1.1. By Distribution Channel
- 10.2.3.2. UAE
- 10.2.3.2.1. By Distribution Channel
- 10.2.3.2.1.1. Supermarkets & Hypermarkets
- 10.2.3.2.1.2. Pharmacy
- 10.2.3.2.1.3. Online Retail
- 10.2.3.2.1. By Distribution Channel
- 10.2.3.3. Rest of Middle East & Africa
- 10.2.3.3.1. By Distribution Channel
- 10.2.3.3.1.1. Supermarkets & Hypermarkets
- 10.2.3.3.1.2. Pharmacy
- 10.2.3.3.1.3. Online Retail
- 10.2.3.3.1. By Distribution Channel
- 10.2.3.1. South Africa
- 10.2.1. By Type
11. Competitive Matrix
- 11.1. Business Strategies Adopted by Leading Players
- 11.2. Global Nicotine Gum Market Revenue Share/Ranking Analysis, By Key Manufacturer
12. Company Profiles
- 12.1. GlaxoSmithKline plc
- 12.1.1. Overview
- 12.1.2. Description
- 12.1.3. Product Portfolio
- 12.1.4. Financials (Data as available in public domain and/or on paid databases)
- 12.1.5. Recent Developments
- 12.2. Novartis Consumer Health
- 12.2.1. Overview
- 12.2.2. Description
- 12.2.3. Product Portfolio
- 12.2.4. Financials (Data as available in public domain and/or on paid databases)
- 12.2.5. Recent Developments
- 12.3. ITC Limited
- 12.3.1. Overview
- 12.3.2. Description
- 12.3.3. Product Portfolio
- 12.3.4. Financials (Data as available in public domain and/or on paid databases)
- 12.3.5. Recent Developments
- 12.4. Johnson & Johnson
- 12.4.1. Overview
- 12.4.2. Description
- 12.4.3. Product Portfolio
- 12.4.4. Financials (Data as available in public domain and/or on paid databases)
- 12.4.5. Recent Developments
- 12.5. Novartis AG
- 12.5.1. Overview
- 12.5.2. Description
- 12.5.3. Product Portfolio
- 12.5.4. Financials (Data as available in public domain and/or on paid databases)
- 12.5.5. Recent Developments
- 12.6. Cipla Health Limited
- 12.6.1. Overview
- 12.6.2. Description
- 12.6.3. Product Portfolio
- 12.6.4. Financials (Data as available in public domain and/or on paid databases)
- 12.6.5. Recent Developments
- 12.7. Perrigo Company Plc
- 12.7.1. Overview
- 12.7.2. Description
- 12.7.3. Product Portfolio
- 12.7.4. Financials (Data as available in public domain and/or on paid databases)
- 12.7.5. Recent Developments
- 12.8. Fertin Pharma
- 12.8.1. Overview
- 12.8.2. Description
- 12.8.3. Product Portfolio
- 12.8.4. Financials (Data as available in public domain and/or on paid databases)
- 12.8.5. Recent Developments
- 12.9. Alchem International
- 12.9.1. Overview
- 12.9.2. Description
- 12.9.3. Product Portfolio
- 12.9.4. Financials (Data as available in public domain and/or on paid databases)
- 12.9.5. Recent Developments
- 12.10. Revolymer
- 12.10.1. Overview
- 12.10.2. Description
- 12.10.3. Product Portfolio
- 12.10.4. Financials (Data as available in public domain and/or on paid databases)
- 12.10.5. Recent Developments
